Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic – Swiss biotech CDR Life has nabbed $76 million in series A bucks to flesh out its multispecific T-cell engagers, a fundraising haul led by Sanofi-backed, Paris investment firm Jeito Capital, which now turns its attention toward bolstering autoimmune programs.
CareHarmony Secures $15 million in Series A Funding Led by Maverick Ventures – NASHVILLE, Tenn.–(BUSINESS WIRE)–CareHarmony, an AI-powered care coordination solutions provider, today announced it has closed a $15 million Series A funding round led by Maverick Ventures, with participation from Nashville Capital Network. The financing comes as CareHarmony continues to experience exponential growth, serving several of the nation’s leading hospitals and health systems through its care platform.
Chamberlain Coffee Raises $7M In Series A Funding Round To Support Brand Growth – LOS ANGELES, Aug. 16, 2022 /PRNewswire/ — Chamberlain Coffee, the brainchild of Youtube phenomenon Emma Chamberlain, announced today the closing of its $7M Series A funding round. The brand, which supports a new generation of coffee drinkers, has secured a cult-like following through its vast selection of offerings and promise of high-quality, organic coffee beans sustainably sourced from around the world and roasted in California. Since its creation in 2019, Chamberlain Coffee has quickly grown a loyal fanbase that has sold out products within hours of launch on multiple occasions. In deeply understanding their audience, the brand has been able to lean heavily on social engagement to create a unique connection with new customers and fans with each story and post, a strategy that has been a key driver for the brand’s heightened success. This funding round will help the brand expand into new channels, and develop new and innovative products to further its mission of being an innovator in the beverage space.
Orna Therapeutics Raises $221 Million Series B Financing to Advance Circular RNA Platform and Accelerate Programs to the Clinic – CAMBRIDGE, Mass., Aug. 16, 2022 /PRNewswire/ — Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies (oRNA), today announced the initial closing of its $221 million Series B financing. At signing, the company received approximately $121 million and expects to receive the remaining $100 million subject to customary closing conditions (including regulatory approval under the Hart-Scott-Rodino (HSR) Act). Merck participated as a new investor in the financing alongside commitments from founding investors MPM Capital and BioImpact Capital, an affiliate of MPM, among others. Orna was created in 2019 by MPM Capital and BioImpact Capital, with funding from the UBS Oncology Impact Fund.
Gorgias Raises $30M in Series C Funding – Gorgias, a San Francisco, CA-based customer service platform designed for ecommerce, raised $30m in Series C funding.
Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis – SAN MATEO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — Bluejay Therapeutics announced today that it has closed a $41 million Series B round of finance led by Arkin Bio Ventures. This round includes participation from other new and existing investors including Synergenics LLC, RiverVest Venture Partners, Yonjin Capital, Octagon Capital and InnoPinnacle International.
Auto Suppliers ZF, Aptiv Lead $88M Series C Funding Round to Advance AVs – ZF and Aptiv, global automotive technology providers with offices in metro Detroit, led an $88 million Series C funding round for South Korea’s StradVision, an AI-based perception processing company for autonomous vehicles and driver assist systems, which also has a Detroit presence.